Shots:
Jazz Pharmaceuticals and partners presented seven abstracts from their oncology development program at ASCO 2025
Robert Iannone, EVP, Global Head of Research and Development, and Chief Medical Officer at Jazz Pharmaceuticals, in an engaging discussion with PharmaShots, shared insights from the P-III IMforte trial assessing Zepzelca plus atezolizumab in first-line maintenance treatment for Extensive…
Precision Medicine in Cancer Treatment: Revolutionizing Patient Care Through Personalized Approaches
Precision medicine has emerged as a transformative approach in cancer treatment, moving away from the traditional one-size-fits-all methodology toward highly individualized therapeutic strategies. This paradigm shift recognizes that each patient's cancer is unique, with distinct genetic profiles, molecular characteristics, and treatment responses that require tailored approaches. By leveraging advanced genomic technologies, biomarker identification, and sophisticated…
Shots:
PharmaShots has compiled a list of US FDA-approved drugs in the month of September 2024
The US FDA has approved a total of 7 new drugs including 4 new molecular entities and 3 biologics leading to the treatment of patients and advances in the healthcare industry
The major highlighted drugs were Roche’s Tecentriq Hybreza & Ocrevus Zunovo for…
Shots:
Recently, Onchilles Pharma unveiled findings from the late-stage preclinical data of its two candidates: N17350 and N17465
Today at PharmaShots, we had an engaging dialogue exchange with Lev Becker, Associate Professor, University of Chicago and Cofounder, Onchilles Pharma
Lev highlights the unique novel mechanism that Onchilles Pharma leverages to treat a wide range of…
The popularity of medical tourism is overgrowing, with the global market projected to reach $31.91 billion by 2023. The industry is expected to experience a 14% cumulative annual growth rate (CAGR) from 2023-2027. Each year, over 10 million patients from different parts of the world seek assistance from doctors overseas. Medical tourism can provide access…

